- Report
- June 2025
- 194 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 192 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 292 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 187 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 216 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 411 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 282 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- June 2025
- 294 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- March 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- March 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- February 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- January 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- May 2025
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- April 2025
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- April 2025
- 187 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- April 2025
- 185 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- March 2025
- 185 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP

The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more